Despite the wide range of treatment options available, metastatic non-small-cell lung cancer (NSCLC) remains a major cause of cancer-related death. For patients with metastatic (EGFR- and ALK-negative/unknown) NSCLC, chemotherapy is still a mainstay of treatment. However, immune checkpoint inhibitors (Opdivo, Keytruda, and most recently Tecentriq) are revolutionizing the treatment algorithm for this subpopulation. As this market segment continues to evolve at a rapid pace, drug manufacturers must understand the unmet needs associated with the treatment of metastatic NSCLC to identify the opportunities for drug development. We focus on this commercially important subpopulation and assess how current therapies perform on key drug attributes and how these attributes affect medical oncologists’ prescribing decisions. We identify potential hidden opportunities and which emerging therapies (if any) could capitalize upon them. Furthermore, we use conjoint analysis to determine attribute and price trade-offs that surveyed medical oncologists are willing to make when considering treatment options for metastatic NSCLC and simulate the share of preference and likelihood to prescribe of different target product profiles.
- What are the treatment drivers and goals for metastatic (EGFR- and ALK-negative/unknown) NSCLC?
- What attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for metastatic (EGFR- and ALK-negative/unknown) NSCLC?
- What are the prevailing areas of unmet need and opportunity in metastatic (EGFR- and ALK-negative/unknown) NSCLC?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new metastatic (EGFR- and ALK-negative/unknown) NSCLC drug?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in December 2016.
Key companies: Bristol-Myers Squibb, Merck & Co., Eli Lilly & Co., Roche/Genentech
Key drugs: Opdivo, Keytruda, Alimta, Avastin
- Non-Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis: EGFR- And ALK-Negative Or Unknown NSCLC (US/EU)
Author(s): Joshua Dawkins, M.Pharmacol., PhD
Joshua Dawkins, M.Pharmacol., Ph.D., is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.